The spleen tyrosine kinase (Syk) regulates Alzheimer amyloid-β production and Tau hyperphosphorylation

Journal of Biological Chemistry

Volumn 289, Issue 49, 2014, Pages 33927-33944

  Paris, Daniel ^a   Ait Ghezala, Ghania ^a   Bachmeier, Corbin ^a   Laco, Gary ^a   Beaulieu Abdelahad, David ^a   Lin, Yong ^a   Jin, Chao ^a   Crawford, Fiona ^a   Mullan, Michael ^a  

^a ROSKAMP INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; ENANTIOMERS; EPITOPES; GLYCOPROTEINS; MAMMALS; PHOSPHORYLATION;

ALZHEIMER AMYLOID; BLOOD-BRAIN BARRIER; GLYCOGEN SYNTHASE KINASE-3; L-TYPE CALCIUM CHANNELS; MECHANISM OF ACTION; PHARMACOLOGICAL INHIBITION; SPLEEN TYROSINE KINASE; TAU HYPERPHOSPHORYLATION;

ENZYMES;

AMYLOID BETA PROTEIN; BAY 61360; BETA SECRETASE 1; CYCLIC AMP DEPENDENT PROTEIN KINASE; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NILVADIPINE; PROTEIN KINASE SYK; PROTEIN KINASE SYK INHIBITOR; TAU PROTEIN; UNCLASSIFIED DRUG; CALCIUM CHANNEL BLOCKING AGENT; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; NIFEDIPINE; PROTEIN TYROSINE KINASE; SIGNAL PEPTIDE;

ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN LEVEL; CHO CELL LINE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; ANALOGS AND DERIVATIVES; ANIMAL; CRICETULUS; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NERVE CELL; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

MUS; MUS MUSCULUS;

AMYLOID BETA-PEPTIDES; ANIMALS; CALCIUM CHANNEL BLOCKERS; CELL LINE, TUMOR; CHO CELLS; CRICETULUS; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEURONS; NF-KAPPA B; NIFEDIPINE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TAU PROTEINS;

EID: 84917707287     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.608091     Document Type: Article

References (80)

1. Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Del Tredici, K., Duyckaerts, C., Frosch, M. P., Haroutunian, V., Hof, P. R., Hulette, C. M., Hyman, B. T., Iwatsubo, T., Jellinger, K. A., Jicha, G. A., Kövari, E., Kukull, W. A., Leverenz, J. B., Love, S., Mackenzie, I. R., Mann, D. M., Masliah, E., McKee, A. C., Montine, T. J., Morris, J. C., Schneider, J. A., Sonnen, J. A., Thal, D. R., Trojanowski, J. Q., Troncoso, J. C., Wisniewski, T., Woltjer, R. L., and Beach, T. G. (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J. Neuropathol. Exp. Neurol. 71, 362-381
2. Santos, A. N., Ewers, M., Minthon, L., Simm, A., Silber, R. E., Blennow, K., Prvulovic, D., Hansson, O., and Hampel, H. (2012) Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. J. Alzheimers Dis. 29, 171-176
3. Doraiswamy, P. M., Sperling, R. A., Coleman, R. E., Johnson, K. A., Reiman, E. M., Davis, M. D., Grundman, M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., Carpenter, A., Clark, C. M., Joshi, A. D., Mintun, M. A., Skovronsky, D. M., Pontecorvo, M. J., and AV45-A11 Study Group (2012) Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 79, 1636-1644
4. Piaceri, I., Nacmias, B., and Sorbi, S. (2013) Genetics of familial and sporadic Alzheimer's disease. Front. Biosci. 5, 167-177
5. Walsh, D. M., and Teplow, D. B. (2012) Alzheimer's disease and the amyloid β-protein. Prog. Mol. Biol. Transl. Sci. 107, 101-124
6. Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., Hoyte, K., Gustafson, A., Liu, Y., Lu, Y., Bhangale, T., Graham, R. R., Huttenlocher, J., Bjornsdottir, G., Andreassen, O. A., Jönsson, E. G., Palotie, A., Behrens, T. W., Magnusson, O. T., Kong, A., Thorsteinsdottir, U., Watts, R. J., and Stefansson, K. (2012) A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 488, 96-99
7. Kero, M., PaeTau, A., Polvikoski, T., Tanskanen, M., Sulkava, R., Jansson, L., Myllykangas, L., and Tienari, P. J. (2013) Amyloid precursor protein (APP) A673T mutation in the elderly Finnish population. Neurobiol. Aging 34, 1518.e1-3
8. Kumar-Singh, S., Theuns, J., Van Broeck, B., Pirici, D., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., and Van Broeckhoven, C. (2006) Mean age-of-onset of familial Alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40. Hum. Mutat. 27, 686-695
9. Pauwels, K., Williams, T. L., Morris, K. L., Jonckheere, W., Vandersteen, A., Kelly, G., Schymkowitz, J., Rousseau, F., Pastore, A., Serpell, L. C., and Broersen, K. (2012) Structural basis for increased toxicity of pathological Aβ42:Aβ40 ratios in Alzheimer disease. J. Biol. Chem. 287, 5650-5660
10. Hefti, F., Goure, W. F., Jerecic, J., Iverson, K. S., Walicke, P. A., and Krafft, G. A. (2013) The case for soluble Aβ oligomers as a drug target in Alzheimer's disease. Trends Pharmacol. Sci. 34, 261-266
11. El-Agnaf, O. M., Mahil, D. S., Patel, B. P., and Austen, B. M. (2000) Oligomerization and toxicity of β-amyloid-42 implicated in Alzheimer's disease. Biochem. Biophys. Res. Commun. 273, 1003-1007
12. Hanger, D. P., Hughes, K., Woodgett, J. R., Brion, J. P., and Anderton, B. H. (1992) Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of Tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci. Lett. 147, 58-62
13. Plattner, F., Angelo, M., and Giese, K. P. (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in Tau hyperphosphorylation. J. Biol. Chem. 281, 25457-25465
14. Hernandez, F., Lucas, J. J., and Avila, J. (2013) GSK3 and Tau: two convergence points in Alzheimer's disease. J. Alzheimers Dis. 33, S141-S144
15. Ly, P. T., Wu, Y., Zou, H., Wang, R., Zhou, W., Kinoshita, A., Zhang, M., Yang, Y., Cai, F., Woodgett, J., and Song, W. (2013) Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes. J. Clin. Invest. 123, 224-235
16. Terwel, D., Muyllaert, D., Dewachter, I., Borghgraef, P., Croes, S., Devijver, H., and Van Leuven, F. (2008) Amyloid activates GSK-3β to aggravate neuronal Tauopathy in bigenic mice. Am. J. Pathol. 172, 786-798
17. Llorens-Martín, M., Jurado, J., Hernández, F., and Avila, J. (2014) GSK-3β, a pivotal kinase in Alzheimer disease. Front. Mol. Neurosci. 7, 46
18. Paris, D., Bachmeier, C., Patel, N., Quadros, A., Volmar, C. H., Laporte, V., Ganey, J., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Crawford, F., and Mullan, M. J. (2011) Selective antihypertensive dihydropyridines lowerAβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier. Mol. Med. 17, 149-162
19. Bachmeier, C., Beaulieu-Abdelahad, D., Mullan, M., and Paris, D. (2011) Selective dihydropyiridine compounds facilitate the clearance of β-amyloid across the blood-brain barrier. Eur. J. Pharmacol. 659, 124-129
20. Paris, D., Quadros, A., Humphrey, J., Patel, N., Crescentini, R., Crawford, F., and Mullan, M. (2004) Nilvadipine antagonizes both Aβ vasoactivity in isolated arteries, and the reduced cerebral blood flow in APPsw transgenic mice. Brain Res. 999, 53-61
21. Kennelly, S. P., Abdullah, L., Paris, D., Parish, J., Mathura, V., Mullan, M., Crawford, F., Lawlor, B. A., and Kenny, R. A. (2011) Demonstration of safety in Alzheimer's patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study. Int. J. Geriatr. Psychiatry. 26, 1038-1045
22. Kennelly, S., Abdullah, L., Kenny, R. A., Mathura, V., Luis, C. A., Mouzon, B., Crawford, F., Mullan, M., and Lawlor, B. (2012) Apolipoprotein E genotype-specific short-term cognitive benefits of treatment with the antihypertensive nilvadipine in Alzheimer's patients-an open-label trial. Int. J. Geriatr. Psychiatry. 27, 415-422
23. Hanyu, H., Hirao, K., Shimizu, S., Iwamoto, T., Koizumi, K., and Abe, K. (2007) Favorable effects of nilvadipine on cognitive function and regional cerebral blood flow on SPECT in hypertensive patients with mild cognitive impairment. Nucl. Med. Commun. 28, 281-287
24. Tokuma, Y., Fujiwara, T., and Noguchi, H. (1987) Determination of (+)-and (-)-nilvadipine in human plasma using chiral stationary-phase liquid chromatography and gas chromatography-mass spectrometry, and a preliminary pharmacokinetic study in humans. J. Pharm. Sci. 76, 310-313
25. Tokuma, Y., and Noguchi, H. (1995) Stereoselective pharmacokinetics of dihydropyridine calcium antagonists. J. Chromatogr. A 694, 181-193
26. Satoh, Y., Okumura, K., and Shiokawa, Y. (1994) Studies on nilvadipine. IV. Synthesis of deuterated and optically active isopropyl 2-cyano-3-methoxycarbonyl-4-(3-nitrophenyl)-6-methyl-1,4-dihydropyridine-5-carboxylate (nilvadipine). Chem. Pharm. Bull. 42, 950-952
27. Rovnyak, G. C., Kimball, S. D., Beyer, B., Cucinotta, G., DiMarco, J. D., Gougoutas, J., Hedberg, A., Malley, M., McCarthy, J. P., and Zhang, R. (1995) Calcium entry blockers and activators: conformational and structural determinants of dihydropyrimidine calcium channel modulators. J. Med. Chem. 38, 119-129
28. Tokuma, Y., Fujiwara, T., Niwa, T., Hashimoto, T., and Noguchi, H. (1989) Stereoselective disposition of nilvadipine, a new dihydropyridine calcium antagonist, in the rat and dog. Res. Commun. Chem. Pathol. Pharmacol. 63, 249-262
29. Koo, E. H., and Squazzo, S. L. (1994) Evidence that production and release of amyloid β-protein involves the endocytic pathway. J. Biol. Chem. 269, 17386-17389
30. Paris, D., Patel, N., Quadros, A., Linan, M., Bakshi, P., Ait-Ghezala, G., and Mullan, M. (2007) Inhibition of Aβ production by NF-κB inhibitors. Neurosci. Lett. 415, 11-16
31. Bachmeier, C., Mullan, M., and Paris, D. (2010) Characterization and use of human brain microvascular endothelial cells to examine β-amyloid exchange in the blood-brain barrier. Cytotechnology 62, 519-529
32. Bachmeier, C. J., Beaulieu-Abdelahad, D., Mullan, M. J., and Paris, D. (2011) Epitope-dependent effects of β-amyloid antibodies on β-amyloid clearance in an in vitro model of the blood-brain barrier. Microcirculation 18, 373-379
33. Bachmeier, C., Beaulieu-Abdelahad, D., Crawford, F., Mullan, M., and Paris, D. (2013) Stimulation of the retinoid X receptor facilitates β-amyloid clearance across the blood-brain barrier. J. Mol. Neurosci. 49, 270-276
34. Bachmeier, C., Beaulieu-Abdelahad, D., Mullan, M., and Paris, D. (2013) Role of the cannabinoid system in the transit of β-amyloid across the blood-brain barrier. Mol. Cell. Neurosci. 56, 255-262
35. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., Prada, C. M., Eckman, C., Younkin, S., Hsiao, K., and Duff, K. (1998) Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4, 97-100
36. Paris, D., Ganey, N. J., Laporte, V., Patel, N. S., Beaulieu-Abdelahad, D., Bachmeier, C., March, A., Ait-Ghezala, G., and Mullan, M. J. (2010) Reduction of β-amyloid pathology by celastrol in a transgenic mouse model of Alzheimer's disease. J. Neuroinflammation 7, 17
37. Paris, D., Beaulieu-Abdelahad, D., Bachmeier, C., Reed, J., Ait-Ghezala, G., Bishop, A., Chao, J., Mathura, V., Crawford, F., and Mullan, M. (2011) Anatabine lowers Alzheimer's Aβ production in vitro and in vivo. Eur. J. Pharmacol. 670, 384-391
38. Duffy, S., Tsao, K. L., and Waugh, D. S. (1998) Site-specific, enzymatic biotinylation of recombinant proteins in Spodoptera frugiperda cells using biotin acceptor peptides. Anal. Biochem. 262, 122-128
39. Schatz, P. J. (1993) Use of peptide libraries to map the substrate specificity of a peptide-modifying enzyme: a 13 residue consensus peptide specifies biotinylation in Escherichia coli. Biotechnology 11, 1138-1143
40. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S. M., Iwata, N., Saido, T. C., Maeda, J., Suhara, T., Trojanowski, J. Q., and Lee, V. M. (2007) Synapse loss and microglial activation precede tangles in a P301S Tauopathy mouse model. Neuron 53, 337-351
41. Acker, C. M., Forest, S. K., Zinkowski, R., Davies, P., and d'Abramo, C. (2013) Sensitive quantitative assays for Tau and phospho-Tau in transgenic mouse models. Neurobiol. Aging 34, 338-350
42. Paris, D., Beaulieu-Abdelahad, D., Ait-Ghezala, G., Mathura, V., Verma, M., Roher, A., Reed, J., Crawford, F., and Mullan, M. (2014) Anatabine attenuates Tau phosphorylation and oligomerization in P301S Tau transgenic mice. Brain Disord. Ther. 3, 126
43. Cheng, X., Shen, Y., and Li, R. (2014) TargetingTNF:a therapeutic strategy for Alzheimer's disease. Drug Discov. Today, 10.1016/j.drudis.2014.06.029
44. Chami, L., Buggia-Prévot, V., Duplan, E., Delprete, D., Chami, M., Peyron, J. F., and Checler, F. (2012) Nuclear factor-κB regulates βAPP and β-and γ-secretases differently at physiological and supraphysiological Aβ concentrations. J. Biol. Chem. 287, 24573-24584
45. Matoba, K., Kawanami, D., Tsukamoto, M., Kinoshita, J., Ito, T., Ishizawa, S., Kanazawa, Y., Yokota, T., Murai, N., Matsufuji, S., and Utsunomiya, K. (2014) Rho-kinase regulation of TNF-α-induced nuclear translocation of NF-κB RelA/p65 and M-CSF expression via p38MAPKin mesangial cells. Am. J. Physiol. Renal Physiol. 307, F571-F580
46. Kim, H. N., Kim, D. H., Kim, E. H., Lee, M. H., Kundu, J. K., Na, H. K., Cha, Y. N., and Surh, Y. J. (2014) Sulforaphane inhibits phorbol ester-stimulated IKK-NF-κB signaling and COX-2 expression in human mammary epithelial cells by targeting NF-κB activating kinase and ERK. Cancer Lett. 351, 41-49
47. Kawauchi, K., Lazarus, A. H., Sanghera, J. S., Man, G. L., Pelech, S. L., and Delovitch, T. L. (1996) Regulation of BCR-and PKC/Ca2+-mediated activation of the Raf1/MEK/MAPK pathway by protein-tyrosine kinase and-tyrosine phosphatase activities. Mol. Immunol. 33, 287-296
48. Liu, D., Kim, D. H., Park, J. M., Na, H. K., and Surh, Y. J. (2009) Piceatannol inhibits phorbol ester-induced NF-κB activation and COX-2 expression in cultured human mammary epithelial cells. Nutr. Cancer 61, 855-863
49. Launay, P., Lehuen, A., Kawakami, T., Blank, U., and Monteiro, R. C. (1998) IgA Fc receptor (CD89) activation enables coupling to Syk and Btk tyrosine kinase pathways: differential signaling after IFN-γ or phorbol ester stimulation. J. Leukocyte Biol. 63, 636-642
50. Hitomi, T., Yanagi, S., Inatome, R., Ding, J., Takano, T., and Yamamura, H. (2001) Requirement of Syk-phospholipase C-γ2 pathway for phorbol ester-induced phospholipase D activation in DT40 cells. Genes Cells 6, 475-485
51. Raeder, E. M., Mansfield, P. J., Hinkovska-Galcheva, V., Shayman, J. A., and Boxer, L. A. (1999) Syk activation initiates downstream signaling events during human polymorphonuclear leukocyte phagocytosis. J. Immunol. 163, 6785-6793
52. Carnevale, J., Ross, L., Puissant, A., Banerji, V., Stone, R. M., DeAngelo, D. J., Ross, K. N., and Stegmaier, K. (2013) SYK regulates mTOR signaling in AML. Leukemia 27, 2118-2128
53. Zhou, Q., and Geahlen, R. L. (2009) The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells. Oncogene 28, 1348-1356
54. Xanthos, D. N., Gaderer, S., Drdla, R., Nuro, E., Abramova, A., Ellmeier, W., and Sandkühler, J. (2011) Central nervous system mast cells in peripheral inflammatory nociception. Mol. Pain 7, 42
55. Yamamoto, N., Takeshita, K., Shichijo, M., Kokubo, T., Sato, M., Nakashima, K., Ishimori, M., Nagai, H., Li, Y. F., Yura, T., Bacon, and K. B. (2003) The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J. Pharmacol. Exp. Ther. 306, 1174-1181
56. Lebouvier, T., Scales, T. M., Hanger, D. P., Geahlen, R. L., Lardeux, B., Reynolds, C. H., Anderton, B. H., and Derkinderen, P. (2008) The microtubule-associated protein Tau is phosphorylated by Syk. Biochim. Biophys. Acta 1783, 188-192
57. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789
58. Li, M., Wang, X., Meintzer, M. K., Laessig, T., Birnbaum, M. J., and Heidenreich, K. A. (2000) Cyclic AMP promotes neuronal survival by phosphorylation of glycogen synthase kinase 3β. Mol. Cell. Biol. 20, 9356-9363
59. Li, H. L., Davis, W. W., Whiteman, E. L., Birnbaum, M. J., and Puré, E. (1999) The tyrosine kinases Syk and Lyn exert opposing effects on the activation of protein kinase Akt/PKB in B lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 96, 6890-6895
60. Yu, S., Huang, H., Iliuk, A., Wang, W. H., Jayasundera, K. B., Tao, W. A., Post, C. B., and Geahlen, R. L. (2013) Syk inhibits the activity of protein kinase A by phosphorylating tyrosine 330 of the catalytic subunit. J. Biol. Chem. 288, 10870-10881
61. Gottesman, R. F., Schneider, A. L., Albert, M., Alonso, A., Bandeen-Roche, K., Coker, L., Coresh, J., Knopman, D., Power, M. C., Rawlings, A., Sharrett, A. R., Wruck, L. M., and Mosley, T. H. (2014) Midlife hypertension and 20-year cognitive change: the atherosclerosis risk in communities neurocognitive study. JAMA Neurol. 71, 1218-1227
62. Forette, F., Seux, M. L., Staessen, J. A., Thijs, L., Birkenhäger, W. H., Babarskiene, M. R., Babeanu, S., Bossini, A., Gil-Extremera, B., Girerd, X., Laks, T., Lilov, E., Moisseyev, V., Tuomilehto, J., Vanhanen, H., Webster, J., Yodfat, Y., and Fagard, R. (1998) Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 352, 1347-1351
63. Seux, M. L., Staessen, J. A., and Forette, F. (1999) Treatment of isolated systolic arterial hypertension and prevention of dementia in aged patients. The Syst-Eur multicenter study. Arch. Mal. Coeur Vaiss. 92, 1083-1087
64. Buggia-Prevot, V., Sevalle, J., Rossner, S., and Checler, F. (2008) NFκB-dependent control of BACE1 promoter transactivation by Aβ42. J. Biol. Chem. 283, 10037-10047
65. Sondag, C. M., Dhawan, G., and Combs, C. K. (2009) β-Amyloid oligomers and fibrils stimulate differential activation of primary microglia. J. Neuroinflammation 6, 1
66. McDonald, D. R., Brunden, K. R., and Landreth, G. E. (1997) Amyloid fibrils activate tyrosine kinase-dependent signaling and superoxide production in microglia. J. Neurosci. 17, 2284-2294
67. Wilkinson, B., Koenigsknecht-Talboo, J., Grommes, C., Lee, C. Y., and Landreth, G. (2006) Fibrillar β-amyloid-stimulated intracellular signaling cascades require Vav for induction of respiratory burst and phagocytosis in monocytes and microglia. J. Biol. Chem. 281, 20842-20850
68. Combs, C. K., Karlo, J. C., Kao, S. C., and Landreth, G. E. (2001)β-Amyloid stimulation of microglia and monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis. J. Neurosci. 21, 1179-1188
69. Combs, C. K., Johnson, D. E., Cannady, S. B., Lehman, T. M., and Landreth, G. E. (1999) Identification of microglial signal transduction pathways mediating a neurotoxic response to amyloidogenic fragments of β-amyloid and prion proteins. J. Neurosci. 19, 928-939
70. Linnartz, B., Wang, Y., and Neumann, H. (2010) Microglial immunoreceptor tyrosine-based activation and inhibition motif signaling in neuroinflammation. Int. J. Alzheimers Dis. 2010, 587463
71. Bhaskar, K., Hobbs, G. A., Yen, S. H., and Lee, G. (2010) Tyrosine phosphorylation of Tau accompanies disease progression in transgenic mouse models of Tauopathy. Neuropathol. Appl. Neurobiol. 36, 462-477
72. Lee, H. R., Shin, H. K., Park, S. Y., Kim, H. Y., Lee, W. S., Rhim, B. Y., Hong, K. W., and Kim, C. D. (2014) Attenuation of β-amyloid-induced Tauopathy via activation of CK2α/SIRT1: targeting for cilostazol. J. Neurosci. Res. 92, 206-217
73. Valera, E., Sánchez-Martín, F. J., Ferrer-Montiel, A. V., Messeguer, A., and Merino, J. M. (2008) NMDA-induced neuroprotection in hippocampal neurons is mediated through the protein kinase A and CREB (cAMP-response element-binding protein) pathway. Neurochem. Int. 53, 148-154
74. O'Driscoll, C., Wallace, D., and Cotter, T. G. (2007) bFGF promotes photoreceptor cell survival in vitro by PKA-mediated inactivation of glycogen synthase kinase 3β and CREB-dependent Bcl-2 up-regulation. J. Neurochem. 103, 860-870
75. Baxter, P. S., Martel, M. A., McMahon, A., Kind, P. C., and Hardingham, G. E. (2011) Pituitary adenylate cyclase-activating peptide induces longlasting neuroprotection through the induction of activity-dependent signaling via the cyclic AMP response element-binding protein-regulated transcription co-activator 1. J. Neurochem. 118, 365-378
76. Liang, Z., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2007) Down-regulation of cAMP-dependent protein kinase by over-activated calpain in Alzheimer disease brain. J. Neurochem. 103, 2462-2470
77. Sierksma, A. S., van den Hove, D. L., Pfau, F., Philippens, M., Bruno, O., Fedele, E., Ricciarelli, R., Steinbusch, H. W., Vanmierlo, T., and Prickaerts, J. (2014) Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology 77, 120-130
78. Fang, F., Chen, X., Huang, T., Lue, L. F., Luddy, J. S., and Yan, S. S. (2012) Multi-faced neuroprotective effects of Ginsenoside Rg1 in an Alzheimer mouse model. Biochim. Biophys. Acta 1822, 286-292
79. Matsuzaki, K., Yamakuni, T., Hashimoto, M., Haque, A. M., Shido, O., Mimaki, Y., Sashida, Y., and Ohizumi, Y. (2006) Nobiletin restoringβ-amyloid-impaired CREB phosphorylation rescues memory deterioration in Alzheimer's disease model rats. Neurosci. Lett. 400, 230-234
80. Gong, B., Vitolo, O. V., Trinchese, F., Liu, S., Shelanski, M., and Arancio, O. (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J. Clin. Invest. 114, 1624-1634